Navigation Links
Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
Date:8/27/2009

TUSTIN, Calif., Aug. 27 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM) today announced that it will release its financial results for the first quarter of fiscal year 2010 on September 3, 2009 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT on the same day.

Peregrine's senior management will discuss financial results for the first quarter ended July 31, 2009 and will review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the archived webcast.

The conference call and webcast will begin at 11:30 a.m. EDT/ 8:30 a.m. PDT. To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit: www.peregrineinc.com. The webcast will be archived on Peregrine's website for 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through September 10, 2009 by calling (877) 344-7529, passcode 431883#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara(R). Peregrine also has in-house manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                                       Media
    info@peregrineinc.com                           Barbara Lindheim
    (800) 987-8256                                  (212) 918-4650


'/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
2. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
3. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
4. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
5. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
6. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
7. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
8. Peregrine Pharmaceuticals Awarded New U.S. Patent Further Strengthening Its Anti-Phospholipid Patent Portfolio
9. Nature Medicine study shows Peregrines bavituximab can cure lethal virus infections
10. Peregrine Pharmaceuticals to Present at the Cowen and Company 29th Annual Health Care Conference
11. Peregrine Pharmaceuticals Bavituximab Achieves Primary Endpoint in First Stage of Phase II Lung Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... 08, 2016 , ... This CAST literature review and report looks at problems ... on the economic effects in countries that are major global commodity exporters and importers, ... resultant risk of low level presence (LLP) puts large volumes of trade worth billions ...
(Date:12/8/2016)... TAMPA, Fla. , Dec. 8, 2016 /PRNewswire/ ... biopharmaceutical company that discovers, develops and plans to ... today that its shares of common stock were approved ... stock will begin trading on the OTCQX, effective ... To qualify for the OTCQX market, companies must ...
(Date:12/8/2016)... , Dec. 8, 2016  Partnering to fuel ... Franklin Technology Partners of Southeastern Pennsylvania ... the parent company of Independence Blue Cross; and Safeguard ... their intentions for a $6 million funding initiative over ... startups. Responding to a burgeoning economic vitality ...
(Date:12/7/2016)... ... December 07, 2016 , ... A new study ... setting of previously treated, advanced pancreatic cancer, liquid biopsies are not yet an ... and timing of blood sampling may improve the value of a blood-based test.” ...
Breaking Biology Technology:
(Date:11/16/2016)... Sensory Inc ., a Silicon ... consumer electronics, and VeriTran , a technology ... today announced a global partnership that will provide ... users of mobile banking and mobile payments solutions.  ... which requires no specialized biometric scanners, yet provides ...
(Date:11/15/2016)... , Nov 15, 2016 Research and ... Global Forecast to 2021" report to their offering. ... ... USD 16.18 Billion by 2021 from USD 6.21 Billion in 2016, ... Growth of the bioinformatics market is driven by the ...
(Date:11/14/2016)... , Nov. 14, 2016  Based ... identification market, Frost & Sullivan recognizes FST ... Sullivan Award for Visionary Innovation Leadership. FST ... the biometric identification market by pioneering In ... solution for instant, seamless, and non-invasive verification. ...
Breaking Biology News(10 mins):